PatternsRadar
Sign in

SAKARSakar Healthcare Limited

NSE
Full chart
1,048.50INR+41.70 (+4.14%)Close · 6 Oct 2026
24 Jul 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹2,333 CrMarket cap
64.6P/E (TTM)
60.2%Delivery

Filings & corporate actions

30 results filed
CSV
Next results · Q2 FY27
Expected 22 Oct 2026 – 7 Nov 2026
Estimate: filed 22–38 days after quarter end, last 5 times
2026
  • 24 JulresultsResults · Q1 FY27 · consolidated and standalone-3.1%NSE
  • 17 JulshareholdingShareholding · 30 Jun 2026-2.1%NSE
  • 12 MayresultsResults · Q4 FY26 · consolidated and standalone+5.2%NSE
  • 17 AprshareholdingShareholding · 31 Mar 2026+0.6%NSE
  • 5 FebresultsResults · Q3 FY26 · consolidated and standalone+6.1%NSE
  • 20 JanshareholdingShareholding · 31 Dec 2025+1.5%NSE

Reaction to results · all yearsrose on day 0 in 10 of 30 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY2724 Jul 2026-3.1%+7.0%+10.3%3.2×
Q4 FY2612 May 2026+5.2%+42.0%+41.0%3.2×
Q3 FY265 Feb 2026+6.1%+15.9%+28.8%15.7×
Q2 FY267 Nov 2025-3.8%+1.2%-3.6%10.2×
Q1 FY2625 Jul 2025-2.7%-6.0%-8.5%0.8×
Q4 FY2515 May 2025-0.9%-1.2%-1.4%0.9×
Q3 FY258 Feb 2025-5.2%-14.0%-12.3%2.3×
Q2 FY2522 Oct 2024-1.8%-4.4%-11.1%1.5×
Q1 FY2513 Aug 2024-3.0%-0.4%+5.7%0.9×
Q4 FY2421 May 20240.0%-3.2%-8.6%0.5×
Q3 FY2410 Feb 2024-10.7%-6.2%-10.3%2.3×
Q2 FY247 Nov 2023-0.9%+4.8%+1.9%0.7×
Q1 FY2414 Aug 2023-0.6%+4.3%+0.6%0.8×
Q4 FY2327 May 2023-4.4%+9.3%+2.6%2.3×
Q3 FY2311 Feb 2023+0.1%-2.5%-2.9%1.6×
Q2 FY2322 Oct 2022-4.3%-6.9%-11.8%0.8×
Q1 FY236 Aug 2022-5.0%-14.8%+12.7%0.2×
Q4 FY2221 May 2022-5.9%-5.4%-8.7%0.9×
Q3 FY228 Feb 2022-2.3%-14.5%-20.2%1.8×
Q2 FY2229 Oct 2021+0.3%-1.7%-10.5%1.2×
Q1 FY2212 Aug 2021-0.8%-12.7%-9.1%1.0×
Q4 FY211 Jun 2021-4.7%-4.6%-0.5%1.4×
Q3 FY215 Feb 2021-2.1%-5.6%-12.4%1.0×
Q2 FY2130 Oct 2020+3.3%-0.2%-4.1%2.5×
Q1 FY2118 Aug 2020+10.0%+11.0%+6.3%2.7×
Q4 FY2025 Jun 2020+2.8%+17.7%+5.1%4.4×
Q3 FY2014 Feb 2020-0.2%-0.6%-11.7%1.0×
Q2 FY2014 Nov 2019+1.0%+1.4%+10.6%1.4×
Q1 FY1913 Sept 2019+4.8%+6.2%0.0%0.7×
Q1 FY2013 Sept 2019+4.8%+6.2%0.0%0.7×
Average-0.8%+0.7%-0.7%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY+38.4%
Profit YoY+120.2%
Interest cost YoY-20.4%
Revenue QoQ+2.6%
Profit QoQ-6.7%
CAGR2Y3Y4Y5Y6Y7Y
Revenue+32.2%+23.7%+21.1%+21.0%——
Profit+79.2%+41.6%+25.8%+25.2%——

Key data

CSV
Open1,013.00
Day range1,013.00 – 1,068.00
52-week range345.50 – 1,229.85
From 52w high-14.7%
RSI (14)48.0
ATR (14)68.17
Volume68.6K
Avg volume (20D)1.54L
Rel volume0.44×
Volatility (1Y)54.1%
Turnover₹7.2Cr
SMA 50 / 200992.64 / 698.13

Delivery percentage

Latest · 6 Oct 202660.2%
20-day avg47.4%
1-year avg53.2%
Percentile (own history)55th
Range0.1–100.0%
Sessions1,727

Over the last 20 sessions SAKAR settled 47.4% of its traded quantity, which is above average for an NSE equity. Its one-year average is 53.2%, so recent sessions are running 5.8 points lower than usual. The latest session ranks higher than 55% of the 1,727 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price+4.14%-3.78%+4.13%+27.35%+103.47%+194.11%

Valuation

CSV
Market cap₹2,333 Cr
P/E (TTM)64.6
EPS (TTM)16.22
Shares outstanding2.22Cr
Listed11 Apr 2019

Ownership

CSV
Promoter52.52%
Promoter Δ QoQ-0.34 pp
Public47.48%
FII12.13%
DII11.37%
Pledged0.00%

Quarterly results · consolidated

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)57.670.371.173.0
YoY chg+34.6%+62.0%+41.5%+38.4%
Net profit (₹ Cr)4.510.211.010.3
YoY chg-5.3%+126.1%+91.4%+120.2%
Net margin7.9%14.6%15.5%14.1%
EPS2.034.594.964.62

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 52.52% · public 47.48%
30 Sept 2021: promoter 67.54%31 Dec 2021: promoter 67.54%31 Mar 2022: promoter 67.54%30 Jun 2022: promoter 67.54%8 Jul 2022: promoter 62.10%30 Sept 2022: promoter 62.10%31 Dec 2022: promoter 62.10%24 Feb 2023: promoter 60.72%31 Mar 2023: promoter 60.72%30 Jun 2023: promoter 60.72%1 Sept 2023: promoter 54.15%30 Sept 2023: promoter 54.15%31 Dec 2023: promoter 53.15%31 Mar 2024: promoter 53.15%30 Jun 2024: promoter 53.15%30 Sept 2024: promoter 53.15%31 Dec 2024: promoter 53.58%31 Mar 2025: promoter 53.58%30 Jun 2025: promoter 52.86%30 Sept 2025: promoter 52.86%31 Dec 2025: promoter 52.86%31 Mar 2026: promoter 52.86%30 Jun 2026: promoter 52.52%
2021-092026-06
  • Promoter
  • Public and others
Promoter
52.52%
Public
47.48%
Promoter change
-0.34 pp
Filed
17 Jul 2026
FII
12.13%
DII
11.37%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27
Revenue from operations34.137.243.141.142.843.450.252.757.670.371.173.0
Other income0.70.20.80.50.40.30.20.41.20.50.21.5
Total income34.737.543.841.643.243.750.453.158.870.971.374.5
Total expenses30.634.539.036.938.038.244.247.753.459.953.259.9
└ Finance costs1.61.82.11.41.61.34.22.11.51.82.41.7
└ Depreciation4.24.44.95.15.15.25.55.65.76.45.96.5
Profit before tax4.23.04.84.75.15.56.25.45.411.018.114.6
Tax expense0.50.91.72.30.30.90.50.70.80.77.04.3
Net profit3.62.13.12.44.84.55.84.74.510.211.010.3
EPS1.680.981.461.102.172.082.662.112.034.594.964.62
Net margin10.67%5.57%7.25%5.86%11.21%10.44%11.47%8.86%7.89%14.57%15.51%14.09%
PBT margin12.18%8.07%11.14%11.43%11.95%12.61%12.41%10.21%9.31%15.57%25.40%19.98%
Tax rate12.42%30.93%34.92%48.71%6.16%17.24%7.62%13.25%15.27%6.42%38.96%29.46%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 24 Jul 2026.

SAKAR at a glance

  • SAKAR closed at ₹1,048.5 on 6 Oct 2026, +4.14% on the day, +194.1% over one year, 14.7% below its 52-week high of ₹1,229.85.
  • Delivery was 60.2% of traded quantity on 6 Oct 2026, the 55th percentile of its own 1,727 sessions with a reading (20-session average 47.4%, 1-year average 53.2%).
  • Market capitalisation is ₹2,333 crore at a trailing P/E of 64.6 (trailing EPS ₹16.22).
  • Q1 FY27 results (consolidated, filed 24 Jul 2026): revenue ₹73 crore (+38.4% year on year), net profit ₹10 crore (+120.2%); the price moved -3.1% on the first session after.
  • Promoters held 52.52% at 30 Jun 2026, down 0.34 percentage points on the previous filing.
  • Q2 FY27 results are expected between 22 Oct 2026 and 7 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE732S01012
SeriesEQ
Listed11 Apr 2019
History from14 Oct 2016
Sessions2,206
Turnover rank#837

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE